Compare Jabil Inc (JBL) vs Eli Lilly And Co (LLY) Price & Performance

Jabil (JBL) trades at $366.10, up 8.75% in 24 hours, reflecting strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with a consensus price target of $448.29, indicating 22% upside. Recent earnings beats and projected AI revenue growth to over $20 billion by fiscal 2027 (UBS, August 11, 2026) support optimism, though high P/E of 44.63 and thin net margins near 2.6% warrant caution.

Outlook is positive with AI-driven expansion, but risks include valuation sensitivity and competitive pressures. Investment appeal hinges on execution of growth forecasts, while volatility may arise from macroeconomic shifts or supply chain disruptions.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.